Sun Pharmaceutical Industries - Fundamental Analysis 2026
- Analysis Date: September 11, 2026
- Exchange: NSE:SUNPHARMA / BSE:524715
- Sector: Pharmaceuticals — Branded Generics, Specialty/Innovative Medicines, API
- Market Cap: Rs. 4,42,245 Cr (Large Cap — India's largest pharma company)
Executive Summary
Fundamental Score: 6.8/10 ⭐⭐⭐⭐
Investment Recommendation: Buy / Accumulate (Medium-High Conviction)
Conviction Level: Medium-High
Target Price: Rs. 2,050 (~11% upside) — 12-month horizon, based on analyst consensus average (~Rs. 2,055, range Rs. 1,650-2,366)
Key Thesis: Sun Pharma is India's largest pharmaceutical company, having successfully built a $1 Bn+ global specialty/innovative medicines franchise (Ilumya, Winlevi, Leqselvi, Cequa) alongside its core branded generics business. FY26 revenue grew to Rs. 58,462 Cr (+11.2% YoY) with Net Profit of Rs. 11,509 Cr, and the balance sheet is near debt-free (D/E ~0.06x) with strong free cash flow. The company trades at a premium PE of 35-38x reflecting its specialty growth story, but faces a persistent, multi-year unresolved FDA import alert at its Halol (Gujarat) facility and continued US small-molecule generics erosion (-9.7% YoY in Q1 FY27). The India domestic business (+16% YoY) and specialty pipeline remain the core growth engines.
Business Overview
Company Profile:
Sun Pharmaceutical Industries Ltd, founded by Dilip Shanghvi, is India's largest pharmaceutical company by market capitalization and revenue. It manufactures and markets branded/generic formulations and APIs globally, with a strategic focus on dermatology, ophthalmology, and onco-dermatology specialty products alongside its core generics business.
Business Model:
- India Branded Generics (~36% of sales): India's largest branded generics player, growing 16% YoY (Q1 FY27) driven by field-force expansion, new launches, and the newly-launched generic semaglutide brands (Noveltreat, Sematrinity).
- US Formulations (~25-29% of sales): 427 Mn (-9.7% YoY) on generics pricing erosion.
- **Global Specialty/Innovative Medicines (crossed 110-125 Mn contribution through FY26-27), and Unloxcyt (skin cancer, newly launched). Q4 FY26 innovative medicines sales were $354 Mn (+20.1% YoY), ~22.2% of quarterly sales.
- Emerging Markets (~19% of sales): Consistent double-digit growth (Q4 FY26 +17.4% YoY).
- API (smallest segment): Rs. 2,185 Cr in FY26, +2.6% YoY — largely captive supply plus third-party sales.
Pipeline: Nidlegy (with partner Philogen, melanoma/skin cancer immunotherapy — EMA MAA resubmitted, registrational studies planned 2026) and continued scaling of recently launched specialty products.
Market Position:
- #1 pharma company in India by market cap and revenue
- Leading global player in dermatology and select onco-dermatology specialty categories
- Key competitors: Dr. Reddy's, Cipla, Lupin (domestic); Teva, Viatris, Mylan (US generics); AbbVie, Novartis (dermatology specialty)
Competitive Moat:
- Scale — India's largest pharma company with the most diversified revenue base across geography and therapy area
- Specialty portfolio moat in dermatology (Ilumya, Winlevi) built over a decade, difficult for peers to replicate quickly
- Highest R&D spend among Indian pharma peers (Rs. 3,554 Cr FY26, ~6.1% of sales), funding continued specialty pipeline depth
- Balance sheet strength (near debt-free) provides flexibility for further specialty M&A/licensing
Management Quality:
- Leadership: Dilip Shanghvi (Founder) transitioned to Executive Chairman as part of a succession plan; Kirti Ganorkar appointed Managing Director effective September 2025 (previously headed the India business since 2019). Jayashree Satagopan is the new CFO; Richard Ascroft leads North America.
- Track Record: Successfully built the company from a domestic generics player into a diversified global specialty pharma leader over three decades; completed the long-running Taro Pharmaceutical take-private merger (June 2024).
- Concerns: Management transition (new MD, new CFO) still in early stages; execution on specialty pipeline scaling remains unproven at the guided $200 Mn+ per-product trajectory.
Corporate Governance:
- Promoter Holding: 54.48% (stable across recent quarters — Mar 2026, Jun 2026 both 54.48%)
- Promoter Pledge: Historically minimal; one secondary (Trendlyne-derived) estimate cites ~1.65% of promoter holding pledged, though this could not be independently verified against a primary BSE/NSE SAST filing this cycle — a related entity (Sun Pharma Advanced Research Co.) confirmed zero encumbrance as of March 31, 2026. Directionally low, not a red flag at this level.
- Institutional Support: FII 14.54% (down from 15.94% Mar 2026), DII 22.06% (up from 21.00% Mar 2026) — DII accumulation offsetting FII selling
Financial Analysis
Revenue and Profit Trends
Annual Performance (Consolidated, Rs. Cr)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 |
| Operating Profit | 10,258 | 11,650 | 13,018 | 15,114 | 16,501 |
| OPM (%) | 27% | 27% | 27% | 29% | 28% |
| Net Profit | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 |
| EPS (Rs.) | 13.64 | 35.32 | 39.91 | 45.55 | 47.84 |
FY22 net profit was depressed by a large one-off Modafinil antitrust litigation settlement charge reflected in negative other income (-Rs. 3,505 Cr). Note: an alternate press-release figure cites FY26 consolidated net profit as Rs. 11,479 Cr (vs. Screener's Rs. 11,509 Cr) — likely a minority-interest adjustment difference.
Quarterly Performance (Recent Quarters, Rs. Cr)
| Quarter | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|
| Sales | 13,291 | 13,675 | 12,959 | 15,300 |
| OPM (%) | 30% | 29% | 29% | ~29% |
| Net Profit | 3,037 | 2,913 | 2,154 | 2,895 |
Q1 FY27 (June 2026): Revenue Rs. 15,300 Cr (+10.5% YoY), Net Profit Rs. 2,895 Cr (+27% YoY), EBITDA margin compressed slightly to 28.9% (vs. 31.06% Q1 FY26) as US sales fell to $427 Mn.
Margin Analysis
| Margin | FY24 | FY25 | FY26 | Trend | Peer Context |
|---|---|---|---|---|---|
| OPM | 27% | 29% | 28% | Stable-to-improving | Best-in-class among large-cap Indian pharma (matches Cipla's pre-FY26 levels) |
| Net Margin | 19.8% | 20.9% | 19.7% | Stable | Strong — reflects near-zero interest costs and specialty mix |
Cash Flow Quality
| Metric | FY26 (Rs. Cr) | Assessment |
|---|---|---|
| Operating Cash Flow | 12,419 | Strong, though down from Rs. 14,072 Cr (FY25) |
| Free Cash Flow | 8,906 | Robust despite higher capex |
| Capex | ~3,600 | Funding specialty manufacturing and API capacity |
| R&D Spend | 3,554 (6.1% of sales) | Highest among Indian pharma peers |
Cash Flow Rating: 8/10
Balance Sheet Strength
| Metric | FY26 (Rs. Cr) | Analysis |
|---|---|---|
| Total Net Worth | 83,570 | Strong equity base |
| Borrowings | 4,627 | Minimal — near debt-free |
| Debt-to-Equity | ~0.06x | Excellent — among the lowest in the sector |
| Book Value/share | Rs. 348 | — |
| Interest Coverage | ~40x (computed) | Very comfortable |
Balance Sheet Rating: 9/10
Shareholding Pattern (India-Specific)
| Category | Jun 2026 | Mar 2026 | QoQ Change | Assessment |
|---|---|---|---|---|
| Promoter Holding | 54.48% | 54.48% | Flat | Stable, healthy majority stake |
| Promoter Pledge | ~low/unverified | — | — | No confirmed red flag; recommend independent SAST verification |
| FII Holding | 14.54% | 15.94% | ↓ | Some FII selling |
| DII Holding | 22.06% | 21.00% | ↑ | Offsetting institutional support |
| Public | 8.81% | 8.48% | ↑ | — |
Shareholding Rating: 7/10
Valuation
| Metric | Sun Pharma | Dr. Reddy's | Cipla | Assessment |
|---|---|---|---|---|
| Current Price | Rs. 1,843-1,874 | Rs. 1,172 | ~Rs. 1,410 | — |
| Market Cap (Rs. Cr) | 4,42,245 | 97,854 | ~1,12,000 | Sun Pharma is ~4.5x Dr. Reddy's, ~4x Cipla |
| PE Ratio | 35.0-37.6x | 30.3x | ~31x | Premium multiple, but justified by specialty growth and balance sheet strength |
| ROE | 16.0% | 11.2% | 11.6% | Best-in-class among the three |
| ROCE | 20.5% | 13.0% | 15.5% | Superior capital efficiency |
| D/E | 0.06x | 0.20x | 0.02x | Cipla marginally lower, but Sun Pharma still very low |
| Dividend Yield | 0.87% | 0.70% | 0.92% | Comparable |
Valuation Verdict: FAIR TO SLIGHTLY EXPENSIVE — the PE premium over peers is supported by superior ROE/ROCE and the specialty franchise, but leaves only moderate margin of safety.
Valuation Rating: 6/10
Fundamental Score: 6.8/10
| Criteria | Score | Rationale |
|---|---|---|
| Business Quality | 8/10 | India's largest pharma, diversified across geography/therapy, $1 Bn+ specialty franchise, highest R&D spend in sector |
| Financial Health | 8/10 | Strong revenue growth, stable 28-29% OPM, near debt-free, robust FCF (Rs. 8,906 Cr FY26) |
| Shareholding Pattern | 7/10 | Promoter 54.48% stable, DII accumulating, pledge status directionally low but not fully independently verified |
| Valuation | 5/10 | PE 35-38x is rich in absolute terms though supported by return ratios; limited margin of safety |
| Growth Prospects | 7/10 | Specialty scaling, India domestic strength (+16%), GLP-1 launch, offset by persistent US generics decline |
| Risk Management | 6/10 | Halol facility's multi-year unresolved FDA import alert is a genuine structural overhang despite otherwise low financial risk |
Composite Score: 6.8/10
Investment Thesis
Bull Case (Target: Rs. 2,200 — ~19% upside)
- Specialty/innovative medicines franchise continues compounding past 200 Mn+ per-product trajectory analysts expect
- India domestic business sustains mid-teens growth, aided by the new generic GLP-1 (semaglutide) launch capturing early market share
- Halol facility resolution (import alert lift) would remove a multi-year overhang and could re-rate the stock
- Near debt-free balance sheet provides dry powder for further specialty M&A/licensing without diluting shareholders
Bear Case (Target: Rs. 1,650 — ~11% downside)
- US generics erosion continues to worsen (already -9.7% YoY in Q1 FY27), dragging consolidated margins
- Halol facility remains under import alert indefinitely, an unresolved multi-year compliance failure
- Specialty pipeline execution disappoints (Nidlegy trial data has been described as "mixed" by partner Philogen)
- New management (MD, CFO transitions) faces execution risk during a critical growth phase
Base Case (Target: Rs. 2,050)
Continued mid-single-digit consolidated growth led by specialty and India, offsetting US generics decline; PE holds in the 33-37x range given superior return ratios and balance sheet quality.
Expected Return Distribution:
- Bull Case (30% probability): +19% upside — Rs. 2,200
- Base Case (50% probability): +11% return — Rs. 2,050
- Bear Case (20% probability): -11% downside — Rs. 1,650
Risk Assessment
| Risk | Probability | Impact | Details |
|---|---|---|---|
| Halol Facility Unresolved | High | Medium | Under FDA import alert since 2023; re-classified OAI (~8 observations) in June 2026 re-inspection — a multi-year, unresolved compliance failure |
| US Generics Erosion | High | Medium | US sales -0.9% FY26, -9.7% YoY Q1 FY27; structural industry-wide pricing pressure |
| Specialty Pipeline Execution | Medium | High | Growth increasingly dependent on scaling Leqselvi, Unloxcyt, Nidlegy to guided targets; unproven at scale |
| Management Transition | Medium | Medium | New MD (Sep 2025), new CFO — execution continuity risk during a critical growth phase |
| Valuation Compression | Medium | Medium | PE 35-38x leaves limited room if specialty growth disappoints |
Overall Risk Rating: MEDIUM (6/10)
Catalysts
Near-term (0-3 months):
- Q2 FY27 results (October-November 2026) — watch India growth sustainability and US decline trajectory
- Any update on Halol facility remediation status
Medium-term (3-12 months):
- Leqselvi and Unloxcyt sales ramp toward guided targets
- Generic semaglutide (Noveltreat/Sematrinity) market share gains in India
Long-term (1-3 years):
- Nidlegy registrational trial results and potential EU/US approval
- Specialty franchise scaling toward a larger share of consolidated revenue, structurally improving margin mix
Key Monitoring Parameters
Quarterly:
- India domestic revenue growth (target: sustain
>12% YoY) - US formulations revenue trend (watch for stabilization vs. continued decline)
- Specialty/innovative medicines revenue run-rate (target: continued growth past $1 Bn annualized)
Trigger Events:
- ✅ Buy more: Halol import alert lifted; specialty products hit guided revenue milestones
- 🔻 Reduce/Exit: Further US generics acceleration downward; specialty pipeline disappointments; new FDA actions at other facilities
Conclusion
Sun Pharma is the highest-quality, most diversified large-cap in the Indian pharma sector — combining India's largest domestic franchise, a genuinely differentiated $1 Bn+ global specialty business, and a near debt-free balance sheet. The stock's premium valuation (PE 35-38x) is largely justified by superior ROE/ROCE versus peers, but the persistent, multi-year unresolved Halol facility FDA import alert and continued US generics erosion temper the otherwise strong bull case. This is a core, buy-on-dips holding for the sector rather than a special-situation trade.
Investment Recommendation: Buy / Accumulate Suitable For: Core long-term pharma sector exposure, moderate-to-aggressive investors Portfolio Allocation: 3-5% of portfolio
Related Analyses
- Indian Pharma Sector Overview
- Dr. Reddy's Laboratories - Fundamental Analysis
- Cipla - Fundamental Analysis
- Divi's Laboratories - Fundamental Analysis
- Biocon - Fundamental Analysis
Disclaimer
This analysis is for educational and informational purposes only and does not constitute investment advice. Conduct your own due diligence and consult a qualified financial advisor before making investment decisions.
Data Sources
- Screener.in — Sun Pharma consolidated financials, ratios, shareholding (Accessed September 11, 2026)
- Business Standard, Angel One, Investing.com — Quarterly results commentary, analyst targets (Accessed September 11, 2026)
- FDA.gov, FiercePharma, Bajaj Broking — Halol facility regulatory status (Accessed September 11, 2026)
Data Timestamp: September 11, 2026 (Stock Price: ~Rs. 1,843-1,874, Market Cap: Rs. 4,42,245 Cr)
Next Update Recommended: After Q2 FY27 earnings (October-November 2026) or any Halol facility regulatory status change